Influence of CYP11B2 Gene Polymorphism on the Prevalence of Hypertension and the Blood Pressure in Japanese Men: Interaction with Dietary Salt IntakeSong Y.a · Miyaki K.a, b · Araki J.a · Zhang L.a · Takahashi Y.b · Nakayama T.b · Muramatsu M.a
aDepartment of Molecular Epidemiology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, and bDepartment of Health Informatics, Kyoto University School of Public Health, Kyoto, Japan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Aims: CYP11B2 gene encodes a key enzyme for the production of aldosterone. Our aim is to investigate the association of –344T/C polymorphism with hypertension in Japanese men. The interaction between genotypes and dietary salt intake was also considered. Methods: Three hundred and ten Japanese male workers participated in this study. Daily salt intake was calculated from a food frequency questionnaire. Melting curve analysis was used to determine CYP11B2 genotypes. Results:There was a significant association between the CT + TT genotype and higher prevalence of hypertension (odds ratio: 3.03; p = 0.014). The association presented in a recessive manner and was strongest in the high-salt intake group (odds ratio: 9.44; p = 0.049). Only in the high-intake group, systolic blood pressure (SBP) was significantly higher in the CT + TT group than in the CC group (p = 0.038). The SBP had a positive correlation with salt intake in the CT + TT group (p for linear trend = 0.021), but not in the CC group (p for interaction = 0.011). Conclusions: CYP11B2 gene –344C/T polymorphism affects the risk of hypertension in Japanese men and high-salt intake levels strengthen this association. This gene-diet interaction warrants further study to elucidate the efficacy of salt restriction as an antihypertensive therapy in different genotypes.
© 2008 S. Karger AG, Basel
White PC: Disorders of aldosterone biosynthesis and action. N Engl J Med 1994;331:250–258.
- Curnow KM, Tusie-Luna MT, Pascoe L, Natarajan R, Gu JL, Nadler JL, White PC: The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex. Mol Endocrinol 1991;5:1513–1522.
- Fardella CE, Miller WL: Molecular biology of mineralocorticoid metabolism. Annu Rev Nutr 1996;16:443–470.
Wagner MJ, Ge Y, Siciliano M, Wells DE: A hybrid cell mapping panel for regional localization of probes to human chromosome 8. Genomics 1991;10:114–125.
- Pascoe L, Curnow KM, Slutsker L, Rösler A, White PC: Mutations in the human CYP11B2 (aldosterone synthase) gene causing corticosterone methyloxidase II deficiency. Proc Natl Acad Sci USA 1992;89:4996–5000.
- Mitsuuchi Y, Kawamoto T, Miyahara K, Ulick S, Morton DH, Naiki Y, Kuribayashi I, Toda K, Hara T, Orii T, Yasuda K, Miura K, Yamamoto Y, Imura H, Shizuta Y: Congenitally defective aldosterone biosynthesis in humans: inactivation of the P-450C18 gene (CYP11B2) due to nucleotide deletion in CMO I deficient patients. Biochem Biophys Res Commun 1993;190:864–869.
- Pascoe L, Curnow KM, Slutsker L, Connell JM, Speiser PW, New MI, White PC: Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci USA 1992;89:8327–8331.
- White PC, Slutsker L: Haplotype analysis of CYP11B2. Endocr Res 1995;21:437–442.
- Pojoga L, Gautier S, Blanc H, Guyene TT, Poirier O, Cambien F, Benetos A: Genetic determination of plasma aldosterone levels in essential hypertension. Am J Hypertens 1998;11:856–860.
Hautanena A, Lankinen L, Kupari M, Jänne OA, Adlercreutz H, Nikkilä H, White PC: Associations between aldosterone synthase gene polymorphism and the adrenocortical function in males. J Intern Med 1998;244:11–18.
- Davies E, Holloway CD, Ingram MC, Inglis GC, Friel EC, Morrison C, Anderson NH, Fraser R, Connell JM: Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension 1999;33:703–707.
Paillard F, Chansel D, Brand E, Benetos A, Thomas F, Czekalski S, Ardaillou R, Soubrier F: Genotype-phenotype relationships for the renin-angiotensin-aldosterone system in a normal population. Hypertension 1999;34:423–429.
Brand E, Chatelain N, Mulatero P, Féry I, Curnow K, Jeunemaitre X, Corvol P, Pascoe L, Soubrier F: Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 1998;32:198–204.
- Tamaki S, Iwai N, Tsujita Y, Kinoshita M: Genetic polymorphism of CYP11B2 gene and hypertension in Japanese. Hypertension 1999;33:266–270.
- Kato N, Sugiyama T, Morita H, Kurihara H, Furukawa T, Isshiki T, Sato T, Yamori Y, Yazaki Y: Comprehensive analysis of the renin-angiotensin gene polymorphisms with relation to hypertension in the Japanese. J Hypertens 2000;18:1025–1032.
Komiya I, Yamada T, Asawa T, Shimabukuro M, Nishimori T, Takasu N: Lys173Arg and –344T/C variants of CYP11B2 in Japanese patients with low-renin hypertension. Hypertension 2000;35:699–703.
Tsuijita Y, Iwai N, Katsuya T, Higaki J, Ogihara T, Tamaki S, Kinoshita M, Mannami T, Ogata J, Baba S: Lack of association between genetic polymorphism of CYP11B2 and hypertension in Japanese: the Suita Study. Hypertens Res 2001;24:105–109.
Tsukada K, Ishimitsu T, Teranishi T, Saitoh M, Yoshii M, Inada H, Ohta S, Akashi M, Minami J, Ono H, Ohrui M, Matsuoka H: Positive association of CYP11B2 gene polymorphism with genetic predisposition to essential hypertension. J Hum Hypertens 2002;16:789–793.
Kumar NN, Benjafield AV, Lin RC, Wang WY, Stowasser M, Morris BJ: Haplotype analysis of aldosterone synthase gene (CYP11B2) polymorphisms shows association with essential hypertension. J Hypertens 2003;21:1249–1253.
- Zhu H, Sagnella GA, Dong Y, Miller MA, Onipinla A, Markandu ND, MacGregor GA: Contrasting associations between aldosterone synthase gene polymorphisms and essential hypertension in blacks and in whites. J Hypertens 2003;21:87–95.
Matsubara M, Sato T, Nishimura T, Suzuki M, Kikuya M, Metoki H, Michimata M, Tsuji I, Ogihara T, Imai Y: CYP11B2 polymorphisms and home blood pressure in a population-based cohort in the Japanese: the Ohasama study. Hypertens Res 2004;27:1–6.
- Rajput C, Makhijani K, Norboo T, Afrin F, Sharma M, Pasha ST, Pasha MA: CYP11B2 gene polymorphisms and hypertension in highlanders accustomed to high salt intake. J Hypertens 2005;23:79–86.
Kupari M, Hautanena A, Lankinen L, Koskinen P, Virolainen J, Nikkila H, White PC: Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 1998;97:569–575.
- Stolarz K, Staessen JA, Kawecka-Jaszcz K, Brand E, Bianchi G, Kuznetsova T, Tikhonoff V, Thijs L, Reineke T, Babeanu S, Casiglia E, Fagard R, Filipovský J, Peleska J, Nikitin Y, Struijker-Boudier H, Grodzicki T: Genetic variation in CYP11B2 and AT1R influences heart rate variability conditional on sodium excretion. Hypertension 2004;44:156–162.
Isaji M, Mune T, Takada N, Yamamoto Y, Suwa T, Morita H, Takeda J, White PC: Correlation between left ventricular mass and urinary sodium excretion in specific genotypes of CYP11B2. J Hypertens 2005;23:1149–1157.
Iwai N, Kajimoto K, Tomoike H, Takashima N: Polymorphism of CYP11B2 determines salt sensitivity in Japanese. Hypertension 2007;49:825–831.
- Zhang L, Miyaki K, Araki J, Song Y, Kimura T, Omae K, Muramatsu M: Interaction of angiotensin I-converting enzyme insertion-deletion polymorphism and daily salt intake influences hypertension in Japanese men. Hypertens Res 2006;29:751–758.
Takahashi K, Yoshimura Y, Kaimoto T, Kunii D, Komatsu T, Yamamoto S: Validation of a food frequency questionnaire based on food groups for estimating individual nutrient intake (in Japanese). Jpn J Nutr 2001;59:221–232.
Tanaka T, Okamura T, Miura K, Kadowaki T, Ueshima H, Nakagawa H, Hashimoto T: A simple method to estimate populational 24-h urinary sodium and potassium excretion using a casual urine specimen. J Hum Hypertens 2002;16:97–103.
- Sookoian S, Gianotti TF, Gonzalez CD, Firola CJ: Association of the C-344T aldosterone synthase gene variant with essential hypertension: a meta-analysis. J Hypertens 2007;25:5–13.
Clyne CD, Zhang Y, Slutsker L, Mathis JM, White PC, Rainey WE: Angiotensin II and potassium regulate human CYP11B2 transcription through common cis-elements. Mol Endocrinol 1997;11:638–649.
- Bassett MH, Zhang Y, Clyne C, White PC, Rainey WE: Differential regulation of aldosterone synthase and 11beta-hydroxylase transcription by steroidogenic factor-1. J Mol Endocrinol 2002;28:125–135.
Willett W, Lenart E: Reproducibility and validity of food-frequency questionnaires; in Willett W (ed): Nutritional Epidemiology, ed 2. New York, Oxford University Press, 1998, pp 101–147.
Svetkey LP, McKeown SP, Wilson AF: Heritability of salt sensitivity in black Americans. Hypertension 1996;28:854–858.
- Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Paccaud F, Shamlaye C: Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 2006;48:239–245.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.